Early Stage Parkinson's Disease Clinical Trial
Official title:
A Randomized, Double Blind, Placebo Controlled Parallel-Group Fixed and Flexible SLV308 Dose Arm Study to Assess Efficacy and Safety of SLV308 Monotherapy in the Treatment of Patients With Early Stage Parkinson's Disease
This study is a multicenter, randomized, double blind, parallel group study of 6 months' treatment with SLV308 administered as a monotherapy in patients with early stage PD. An open label safety extension to this study is planned as a separate protocol for patients who are willing and eligible to participate.
n/a
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT00623324 -
The Effects of Aplindore on the Treatment of Signs and Symptoms of Parkinson's Disease
|
Phase 2 | |
| Completed |
NCT00332917 -
An Open Label SLV308 Safety Extension to Study S308.3.001 in Early PD Patients
|
Phase 3 | |
| Completed |
NCT00335374 -
An Open Label SLV308 Safety Extension to Study S308.3.003 in Early PD Patients
|
Phase 3 | |
| Completed |
NCT00599196 -
An Open-Label Extension Trial to Assess the Safety of Long-Term Treatment of Rotigotine in Early-Stage Parkinson's Disease
|
Phase 3 |